|
GB9816837D0
(en)
|
1998-08-04 |
1998-09-30 |
Zeneca Ltd |
Amide derivatives
|
|
AU3653099A
(en)
|
1998-04-17 |
1999-11-08 |
Parker Hughes Institute |
Btk inhibitors and methods for their identification and use
|
|
BR9912729A
(pt)
|
1998-08-04 |
2001-05-02 |
Astrazeneca Ab |
Derivado de amida, processo para prepará-lo, e, uso do mesmo
|
|
ATE254105T1
(de)
|
1998-09-25 |
2003-11-15 |
Astrazeneca Ab |
Benzamid-derivate und ihre verwendung als cytokine inhibitoren
|
|
US6306897B1
(en)
|
1999-03-19 |
2001-10-23 |
Parker Hughes Institute |
Calanolides for inhibiting BTK
|
|
KR20020088406A
(ko)
|
1999-09-17 |
2002-11-27 |
애보트 게엠베하 운트 콤파니 카게 |
치료제로서의 피라졸로피리미딘
|
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
|
EP1434579B1
(en)
|
2001-10-09 |
2011-06-08 |
Amgen Inc. |
Imidazole derivatives as antiinflammatory agents
|
|
AU2003262642B2
(en)
|
2002-08-14 |
2010-06-17 |
Vertex Pharmaceuticals Incorporated |
Protein kinase inhibitors and uses thereof
|
|
MXPA05006033A
(es)
|
2002-12-05 |
2006-03-08 |
Univ Arkansas |
Determinantes moleculares de enfermedad osea por mieloma, y usos de los mismos.
|
|
JP4896518B2
(ja)
|
2002-12-13 |
2012-03-14 |
ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド |
ニコチンアミド系キナーゼ阻害薬
|
|
BRPI0418031A
(pt)
|
2003-12-22 |
2007-04-17 |
Gilead Sciences Inc |
inibidores de quinase fosfonato-substituìdos
|
|
TW200616974A
(en)
|
2004-07-01 |
2006-06-01 |
Astrazeneca Ab |
Chemical compounds
|
|
PE20060664A1
(es)
|
2004-09-15 |
2006-08-04 |
Novartis Ag |
Amidas biciclicas como inhibidores de cinasa
|
|
CA2590750A1
(en)
|
2004-12-20 |
2006-06-29 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Myd88 homodimerization inhibitors
|
|
TW200634003A
(en)
|
2004-12-22 |
2006-10-01 |
Astrazeneca Ab |
Chemical compounds
|
|
AR053992A1
(es)
|
2004-12-22 |
2007-05-30 |
Astrazeneca Ab |
Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
|
|
KR100919905B1
(ko)
|
2005-01-26 |
2009-10-06 |
아이알엠 엘엘씨 |
단백질 키나제 억제제로서의 화합물 및 조성물
|
|
US7605154B2
(en)
|
2005-08-08 |
2009-10-20 |
Janssen Pharmaceutica N.V. |
Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
|
|
US7754717B2
(en)
|
2005-08-15 |
2010-07-13 |
Amgen Inc. |
Bis-aryl amide compounds and methods of use
|
|
GT200600411A
(es)
|
2005-09-13 |
2007-05-21 |
Novartis Ag |
Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
|
|
EP1957461B1
(en)
|
2005-11-14 |
2016-11-02 |
Genentech, Inc. |
Bisamide inhibitors of hedgehog signaling
|
|
CA2632929A1
(en)
|
2005-12-22 |
2007-06-28 |
Astrazeneca Ab |
Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
|
|
WO2007076474A1
(en)
*
|
2005-12-23 |
2007-07-05 |
Kalypsys, Inc. |
Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
|
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
|
US20090312396A1
(en)
*
|
2006-07-10 |
2009-12-17 |
Astrazeneca Ab |
Methods for cancer treatment using tak1 inhibitors
|
|
EP2529621B1
(en)
|
2006-09-22 |
2016-10-05 |
Pharmacyclics LLC |
Inhibitors of bruton's tyrosine kinase
|
|
SI2066351T1
(sl)
|
2006-10-02 |
2016-02-29 |
E.R. Squibb & Sons, L.L.C. |
Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
|
|
US20120065201A1
(en)
|
2007-03-28 |
2012-03-15 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
WO2008125691A2
(en)
|
2007-04-17 |
2008-10-23 |
Novartis Ag |
Ethers of naphtalene carboxylic acid amides as cancer cure
|
|
WO2008144253A1
(en)
|
2007-05-14 |
2008-11-27 |
Irm Llc |
Protein kinase inhibitors and methods for using thereof
|
|
TW200906825A
(en)
|
2007-05-30 |
2009-02-16 |
Scripps Research Inst |
Inhibitors of protein kinases
|
|
US7928140B2
(en)
|
2007-08-02 |
2011-04-19 |
Amgen Inc. |
Benzothiazole PI3 kinase modulators for cancer treatment
|
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
JP5600063B2
(ja)
*
|
2007-10-19 |
2014-10-01 |
セルジーン アビロミクス リサーチ， インコーポレイテッド |
ヘテロアリール化合物およびその使用
|
|
KR20100058660A
(ko)
|
2007-10-23 |
2010-06-03 |
테바 파마슈티컬 인더스트리즈 리미티드 |
다사티닙 다형체 및 이의 제조 방법
|
|
US8394816B2
(en)
|
2007-12-07 |
2013-03-12 |
Irene Ghobrial |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
|
|
WO2009076373A1
(en)
|
2007-12-10 |
2009-06-18 |
Concert Pharmaceuticals Inc. |
Heterocyclic kinase inhibitors
|
|
CA2723237A1
(en)
|
2008-05-06 |
2009-11-12 |
Peter A. Blomgren |
Substituted amides, method of making, and use as btk inhibitors
|
|
AU2009262068C1
(en)
*
|
2008-06-27 |
2015-07-02 |
Celgene Car Llc |
Heteroaryl compounds and uses thereof
|
|
US7824861B2
(en)
|
2008-07-10 |
2010-11-02 |
National Tsing Hua University |
Method for quantitative analysis of transcripts with nucleotide polymorphism at specific site
|
|
LT3081552T
(lt)
|
2008-08-13 |
2021-06-10 |
Mitsui Chemicals Agro, Inc. |
Kenkėjų kontrolės agentas, turintis amido darinį ir kenkėjų kontrolės agento panaudojimas
|
|
CA2735208A1
(en)
|
2008-09-02 |
2010-03-11 |
Boehringer Ingelheim International Gmbh |
Novel benzamides, production thereof, and use thereof as medicaments
|
|
WO2010056875A1
(en)
|
2008-11-12 |
2010-05-20 |
Cgi Pharmaceuticals, Inc. |
Pyridazinones and their use as btk inhibitors
|
|
CA2746120A1
(en)
|
2008-12-23 |
2010-07-01 |
Genentech, Inc. |
Methods and compositions for diagnostic use in cancer patients
|
|
MX2012002591A
(es)
*
|
2009-09-03 |
2012-04-02 |
Allergan Inc |
Compuestos como moduladores de tirosina cinasas.
|
|
WO2011029043A1
(en)
|
2009-09-04 |
2011-03-10 |
Biogen Idec Ma Inc. |
Heteroaryl btk inhibitors
|
|
EP2937345B1
(en)
*
|
2009-12-29 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
|
US8658794B2
(en)
|
2010-02-08 |
2014-02-25 |
Merck Sharp & Dohme B.V. |
8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof
|
|
US20120071497A1
(en)
|
2010-06-03 |
2012-03-22 |
Pharmacyclics, Inc. |
Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
|
|
JP5985473B2
(ja)
|
2010-07-13 |
2016-09-06 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
|
|
AU2011328237A1
(en)
*
|
2010-11-09 |
2013-05-23 |
Cellzome Limited |
Pyridine compounds and aza analogues thereof as TYK2 inhibitors
|
|
EP2640366A2
(en)
|
2010-11-15 |
2013-09-25 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
|
|
LT2714677T
(lt)
|
2011-05-23 |
2018-12-10 |
Merck Patent Gmbh |
Piridino ir pirazino dariniai
|
|
US9073947B2
(en)
|
2011-06-10 |
2015-07-07 |
Merck Patent Gmbh |
Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
|
|
ES2624981T3
(es)
|
2011-07-01 |
2017-07-18 |
Dana-Farber Cancer Institute, Inc. |
Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
|
|
EP2548877A1
(en)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
|
JP2014528957A
(ja)
|
2011-10-03 |
2014-10-30 |
シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト |
殺虫性化合物
|
|
EP2763994A4
(en)
|
2011-10-04 |
2015-08-26 |
Gilead Calistoga Llc |
NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
|
|
TW201326171A
(zh)
|
2011-11-03 |
2013-07-01 |
Genentech Inc |
烷基化哌□化合物
|
|
HUE043001T2
(hu)
|
2011-11-09 |
2019-07-29 |
Bristol Myers Squibb Co |
Hematológiai malignómák kezelése anti-CXCR4 antitesttel
|
|
JP6106685B2
(ja)
|
2011-11-17 |
2017-04-05 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
|
|
ES2661510T3
(es)
|
2011-12-15 |
2018-04-02 |
Novartis Ag |
Uso de inhibidores de la actividad o función de PI3K
|
|
JP6327713B2
(ja)
|
2012-07-27 |
2018-05-23 |
国立研究開発法人理化学研究所 |
急性骨髄性白血病の治療又は再発抑制剤
|
|
CN103405429A
(zh)
|
2013-08-22 |
2013-11-27 |
中国药科大学 |
一类vegfr-2抑制剂及其用途
|
|
CA2922398C
(en)
|
2013-09-12 |
2023-08-29 |
Dana-Farber Cancer Institute, Inc. |
Methods for evaluating and treating waldenstrom's macroglobulinemia
|
|
WO2015069287A1
(en)
|
2013-11-08 |
2015-05-14 |
Allergan, Inc. |
Compounds as tyrosine kinase modulators
|
|
CA2930326C
(en)
|
2013-12-06 |
2022-09-06 |
Dana-Farber Cancer Institute, Inc. |
Methods to distinguish waldenstrom's macroglobulinemia from igm monoclonal gammopathy of undetermined significance
|
|
USRE50030E1
(en)
|
2013-12-13 |
2024-07-02 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
EP3079682A4
(en)
|
2013-12-13 |
2017-08-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
WO2016055982A1
(en)
|
2014-10-10 |
2016-04-14 |
Acerta Pharma B.V. |
Quinoline and quinazoline compounds
|
|
CA2965178C
(en)
|
2014-10-22 |
2023-09-26 |
Dana-Farber Cancer Institute, Inc. |
Thiazolyl-containing compounds for treating proliferative diseases
|
|
IL295472B2
(en)
|
2016-03-28 |
2024-10-01 |
Presage Biosciences Inc |
Pharmaceutical combinations for the treatment of cancer
|
|
JP2019518006A
(ja)
|
2016-04-29 |
2019-06-27 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ
|
|
CN106008371A
(zh)
|
2016-06-24 |
2016-10-12 |
谢阳 |
1-芳基脲基环烷基-1-甲酰胺类化合物及其药物组合物和应用
|
|
CN106279120A
(zh)
|
2016-07-15 |
2017-01-04 |
谢阳 |
一种n‑芳基氨基甲酰基脯氨酸类化合物及其药物组合物和应用
|
|
CN107056786B
(zh)
|
2016-10-14 |
2019-05-07 |
苏州明锐医药科技有限公司 |
阿卡替尼的制备方法
|
|
WO2018215668A1
(en)
|
2017-05-26 |
2018-11-29 |
Glenmark Pharmaceuticals S.A. |
Novel inhibitors of map4k1
|
|
US12679842B2
(en)
|
2019-10-08 |
2026-07-14 |
Dana-Farber Cancer Institute, Inc. |
HCK as a therapeutic target in MYD88 mutated diseases
|
|
CN114746095B
(zh)
|
2019-10-08 |
2025-01-24 |
达纳-法伯癌症研究所有限公司 |
Hck作为myd88突变疾病的治疗靶点
|